Azevan Pharmaceuticals is a clinical-stage pharmaceutical company committed to developing new medicines for treating disorders of the central nervous system (CNS). Their research focuses on stress-related and neuropsychiatric conditions with significant unmet medical needs. Azevan's pipeline includes novel compounds targeting vasopressin 1a (V1a) receptors, such as SRX246, which has been investigated for conditions like intermittent explosive disorder (IED), post-traumatic stress disorder (PTSD), and other stress-related psychiatric disorders. The company aims to provide innovative therapeutic options that improve the lives of patients suffering from these challenging conditions.
The headquarters serves as the central hub for Azevan's research and development operations, clinical trial management, strategic planning, and corporate administration.
Located within Ben Franklin TechVentures, an award-winning technology incubator/post-incubator, providing access to state-of-the-art facilities, lab space, and a collaborative environment conducive to biotech innovation.
The work culture is likely focused on scientific rigor, innovation, and collaboration, driven by the mission to develop impactful CNS therapies. As a clinical-stage company, the environment is probably dynamic and results-oriented.
The Bethlehem headquarters is significant as it places Azevan within a supportive ecosystem for biotechnology startups and research, facilitating access to talent, resources, and potential partnerships in the Lehigh Valley.
As a clinical-stage company, Azevan Pharmaceuticals' global presence is primarily related to its clinical trial activities. They may conduct trials at various sites internationally to ensure diverse patient populations and efficient recruitment for their CNS drug candidates. They might also collaborate with international research institutions or contract research organizations (CROs) to support their development programs.
1770 Bathgate Road, Suite 302
Bethlehem
Pennsylvania
United States
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Azevan Pharmaceuticals' leadership includes:
Azevan Pharmaceuticals has been backed by several prominent investors over the years, including:
No major executive hires or exits have been publicly announced by Azevan Pharmaceuticals in the last 12 months. The leadership team appears to be stable based on available information.
Discover the tools Azevan Pharmaceuticals uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Azevan Pharmaceuticals likely utilizes standard professional email formats. The most common format for companies of this nature is typically the first initial followed by the last name, or the full first name followed by the last name.
[first_initial][last]@azevan.com
Format
nsimon@azevan.com
Example
80%
Success rate
Azevan Pharmaceuticals News • June 28, 2023
Azevan Pharmaceuticals announced that positive results from its Phase 2 proof-of-concept study of SRX246 for the treatment of Intermittent Explosive Disorder (IED) have been published in The Journal of Clinical Psychiatry. The study demonstrated that SRX246 was well-tolerated and showed a statistically significant reduction in aggression compared to placebo....more
GlobeNewswire • March 1, 2022
Azevan Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to SRX246 for the treatment of Intermittent Explosive Disorder (IED). This designation facilitates the development and expedites the review of drugs to treat serious conditions and fill an unmet medical need....more
Azevan Pharmaceuticals News • November 10, 2021
Azevan Pharmaceuticals announced positive topline results from its Phase 2 proof-of-concept study evaluating SRX246 for the treatment of Intermittent Explosive Disorder (IED) in adults. The study met its primary endpoint, showing a statistically significant reduction in aggression....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Azevan Pharmaceuticals, are just a search away.